Moderna (MRNA) ended the recent trading session at $27.54, demonstrating a +2.53% change from the preceding day's closing price. The stock's performance was ahead of the S&P 500's daily gain of 0.8%.

Moderna’s stock price has taken a beating over the past six months, shedding 33.6% of its value and falling to $26.85 per ...

The FDA has approved its requested updated versions of expanded warning labels for COVID-19 vaccines. As Healio previously ...

Labels for the Pfizer and Moderna shots, which already caution about myocarditis and pericarditis, will more strongly stress ...

First, let's back up a bit and take a look at the Moderna story, from the glory days of a few years ago to its troubles today. As mentioned, Moderna sprang to the forefront in 2021 to 2022, bringing ...

Moderna had been awarded over $750 million to develop a vaccine against bird flu, which has been circulating in farm animals and sickening people.

Post pandemic, Moderna Inc. is broadening the applications of mRNA technology to cancer, rare diseases, latent viruses and ...

The FDA has approved required updates to the labeling of Pfizer’s Comirnaty and Moderna’s Spikevax COVID-19 vaccines to include revised warnings about the risk of myocarditis and pericarditis ...

The Trump administration has canceled $766 million awarded to drugmaker Moderna Inc. to develop a vaccine against potential pandemic influenza viruses, including H5N1 bird flu.

The FDA expanded the approval of Moderna’s RSV vaccine, extending the license to include more adults and giving the company a ...

Moderna's shares fell 2.3% on Friday on concerns about whether a new CDC advisory panel would back the use of the company's ...